Overall, the number of patients discharged from hospitals with an ulcerative colitis diagnosis increased between 2009 and 2018, but the number of patients opting for ileal pouch–anal anastomosis (IPAA ...

Vedolizumab appears to be effective at reducing intestinal inflammation and inducing remission in patients who developed chronic pouchitis after undergoing ileal pouch-anal anastomosis (IPAA) for ...

"The early identification of patients at risk for the development of pouchitis remains an unmet need given that patients developing pouchitis in the first year after IPAA have demonstrated an ...

Pouchitis is the most common condition that develops following ileal pouch-anal anastomosis. More than one-half of patients with ulcerative colitis (UC) develop intermittent pouchitis within 1 year ...

An eight-strain probiotic has been shown to reduce the risk for pouchitis in patients with ulcerative colitis who undergo ileal pouch anal anastomosis (IPAA), but its cost-effectiveness depends on ...

"These findings are significant, as individuals with delayed closure for nonmedical reasons or pouch complications do not have heightened risk of developing endoscopic pouch inflammation, and, ...

If you have ulcerative colitis (UC), your first line of treatment will likely be medication. But even with medication, sometimes symptoms continue to flare, tanking your quality of life along the way.

Mark Gurarie is a writer covering health topics, technology, music, books, and culture. He also teaches health science and research writing at George Washington University's School of Medical and ...